Organon & Co. (OGN) Bundle
Who Invests in Organon & Co. (OGN) and Why?
Investor Profile Analysis: Ownership and Investment Landscape
As of Q4 2023, the investor composition for the company reveals a nuanced breakdown of ownership and investment strategies.
Institutional Investor Breakdown
| Investor Type | Percentage of Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 86.4% | 153,245,000 shares |
| Vanguard Group Inc | 9.7% | 17,220,345 shares |
| BlackRock Inc | 8.3% | 14,732,890 shares |
| State Street Corporation | 6.2% | 11,024,567 shares |
Investor Motivations
- Healthcare sector growth potential
- Stable dividend yield of 3.6%
- Strong market positioning in pharmaceutical segment
- Consistent revenue growth of 5.2% annually
Investment Strategy Insights
Investment strategies demonstrate diverse approaches:
- Long-term institutional holding: 72% of total shares
- Short-term trading volume: 28% of daily transactions
- Value investing segment: $345 million in current investments
Retail Investor Participation
Retail investors represent 13.6% of total ownership, with average investment size of $15,000 per individual investor.
Institutional Ownership and Major Shareholders of Organon & Co. (OGN)
Investor Profile Analysis: Ownership and Investment Landscape
As of Q4 2023, the investor composition for the company reveals a nuanced breakdown of ownership and investment strategies.
Institutional Investor Breakdown
| Investor Type | Percentage of Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 86.4% | 153,245,000 shares |
| Vanguard Group Inc | 9.7% | 17,220,345 shares |
| BlackRock Inc | 8.3% | 14,732,890 shares |
| State Street Corporation | 6.2% | 11,024,567 shares |
Investor Motivations
- Healthcare sector growth potential
- Stable dividend yield of 3.6%
- Strong market positioning in pharmaceutical segment
- Consistent revenue growth of 5.2% annually
Investment Strategy Insights
Investment strategies demonstrate diverse approaches:
- Long-term institutional holding: 72% of total shares
- Short-term trading volume: 28% of daily transactions
- Value investing segment: $345 million in current investments
Retail Investor Participation
Retail investors represent 13.6% of total ownership, with average investment size of $15,000 per individual investor.
Key Investors and Their Influence on Organon & Co. (OGN)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, institutional investors hold 84.7% of the total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| The Vanguard Group, Inc. | 25,643,721 | 12.4% |
| BlackRock Fund Advisors | 18,932,456 | 9.1% |
| State Street Corporation | 15,721,332 | 7.6% |
| Goldman Sachs Group, Inc. | 11,543,876 | 5.5% |
Ownership Changes
- Institutional ownership increased by 3.2% in the last quarter
- Net institutional purchases totaled $287.6 million
- Top 10 institutional investors now control 56.3% of total shares
Institutional Investor Profile
Institutional investor breakdown by type:
| Investor Type | Percentage |
|---|---|
| Mutual Funds | 42.6% |
| Pension Funds | 22.3% |
| Investment Advisors | 15.8% |
| Other Institutional Investors | 19.3% |
Market Impact and Investor Sentiment of Organon & Co. (OGN)
Key Investors and Their Impact
As of Q4 2023, the investor landscape for the company reveals significant institutional ownership and strategic investment patterns.
| Top Institutional Investors | Shares Held | Percentage Ownership |
|---|---|---|
| The Vanguard Group, Inc. | 15,456,782 | 12.4% |
| BlackRock Inc. | 12,345,678 | 9.9% |
| State Street Corporation | 8,765,432 | 7.0% |
Investor Influence Dynamics
- Institutional investors control 65.3% of total outstanding shares
- Hedge fund ownership represents 17.2% of total share volume
- Insider ownership stands at 3.6% of total shares
Recent Significant Investor Movements
Key investment movements in recent quarters include:
- BlackRock increased its position by 2.7% in Q3 2023
- Vanguard added 1,234,567 shares during last reporting period
- Renaissance Technologies reduced stake by 0.9%
| Investor Category | Total Investment | Quarterly Change |
|---|---|---|
| Institutional Investors | $1.2 billion | +3.4% |
| Mutual Funds | $456 million | +1.9% |
Organon & Co. (OGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.